Research programme: anticancer therapeutics - EpiCept Corporation
Alternative Names: BCH 19746; BCH 23540; CV 2105; CV 58151; EPC 2105; EPC 58151; MX 116407; MX 2105; MX 58151Latest Information Update: 17 Mar 2008
At a glance
- Originator EpiCept Corporation
- Class Nitriles
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 17 Mar 2008 Discontinued - Preclinical for Cancer in USA (IV)
- 17 Mar 2008 Discontinued - Preclinical for Solid tumours in Canada (IV)
- 05 Oct 2006 EpiCept has filed an IND with the US FDA for EPC 2407 for cancer